<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312474085</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312474085</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Vanin-1 as a potential novel biomarker for active nephritis in systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sánchez-Muñoz</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474085">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Amezcua-Guerra</surname><given-names>LM</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474085">1</xref>
<xref ref-type="aff" rid="aff2-0961203312474085">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203312474085"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Macías-Palacios</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474085">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Márquez-Velasco</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474085">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bojalil</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474085">1</xref>
<xref ref-type="aff" rid="aff3-0961203312474085">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312474085"><label>1</label>Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico</aff>
<aff id="aff2-0961203312474085"><label>2</label>Doctoral-degree program, Biological and Health Sciences, Universidad Autónoma Metropolitana, Mexico</aff>
<aff id="aff3-0961203312474085"><label>3</label>Department of Health Care, Universidad Autónoma Metropolitana, Mexico</aff>
<author-notes>
<corresp id="corresp1-0961203312474085">Luis M. Amezcua-Guerra, Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano 1, Sección XVI, CP 14080, Tlalpan, Mexico City, Mexico. Email: <email>lmamezcuag@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>333</fpage>
<lpage>335</lpage>
<history>
<date date-type="received"><day>11</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>17</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2012. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Sir,</p>
<p>Renal involvement in systemic lupus erythematosus (SLE) is relevant as nephritis (LN) occurs in more than half of patients followed over time.<sup><xref ref-type="bibr" rid="bibr1-0961203312474085">1</xref></sup> Histology is the mainstay to define active renal damage, but complications associated with biopsy have led to a search for noninvasive surrogate markers.<sup><xref ref-type="bibr" rid="bibr2-0961203312474085">2</xref></sup></p>
<p>Vanin-1 belongs to a novel enzymatic pathway licensing inflammation, oxidative stress, and cell migration via cysteamine; this pantetheinase has broad tissue expression but peaks in the kidney epithelium and peripheral leukocytes.<sup><xref ref-type="bibr" rid="bibr3-0961203312474085">3</xref></sup> Vanin-1 levels are useful to sense acute renal injury induced by organic solvents, drugs, and diabetes.<sup><xref ref-type="bibr" rid="bibr4-0961203312474085">4</xref><xref ref-type="bibr" rid="bibr5-0961203312474085"/><xref ref-type="bibr" rid="bibr6-0961203312474085"/>–<xref ref-type="bibr" rid="bibr7-0961203312474085">7</xref></sup></p>
<p>To investigate whether vanin-1 could be a marker for LN, we conducted a cross-sectional study including 20 patients fulfilling the 1997 criteria for the classification of SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203312474085">8</xref></sup> Seven patients were considered to have active renal damage as defined by &gt;0.5 g/24-hour urine proteins, &gt;5 white or red blood cells/high power field of unspun urine, or urinary casts. Disease activity (systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K)) and cumulative organ damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology cumulative damage index (SLICC/ACR)) were assessed.<sup><xref ref-type="bibr" rid="bibr9-0961203312474085">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203312474085">10</xref></sup> Twelve patients with rheumatoid arthritis (RA) were included as nonrenal, autoimmune reference.<sup><xref ref-type="bibr" rid="bibr11-0961203312474085">11</xref></sup> Patients with clinically suspected infection, end-stage renal disease or using thiazolidinediones were not included. Protocol was approved by the local ethics committee, and informed consents were obtained.</p>
<p>Fasting blood and urine samples were obtained from all individuals. Vanin-1 mRNA was measured in total leukocytes by real-time-quantitative polymerase chain reaction (RT-qPCR) in LightCycler 2.0 using validated assays from the Universal Probe Library (Roche, GER): <italic>VNN1</italic> (NM_004666) 5′-TCCTGAGGTGTTGCTGAGTG-3′, and 5′-AGCGTCCGTCAGTTGACAC-3′; <italic>GAPDH</italic> (NM_002046) 5′-AGCCACATCGCTCAGACAC-3′, and 5′-GCCCAATACGACCAAATCC-3′. Additionally, several prototypal cytokines were measured in serum and urine by enzyme-linked immunosorbent assay (ELISA) (R&amp;D Systems, USA).</p>
<p>Data are presented as percentages or means (±SD). Differences were calculated using Fisher’s exact test or Mann-Whitney test as appropriate. Spearman’s ρ coefficients (95% confidence intervals) were calculated. <italic>P</italic> &lt; 0.05 was set for significance.
<table-wrap id="table1-0961203312474085" position="float"><label>Table 1</label><caption><p>Main data from patients with systemic lupus erythematosus or rheumatoid arthritis</p></caption>
<graphic alternate-form-of="table1-0961203312474085" xlink:href="10.1177_0961203312474085-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2"/><th align="center" colspan="3">SLE (n = 20)<hr/></th>
<th align="center" rowspan="2"><italic>p</italic> value</th>
<th align="center" rowspan="2">RA (<italic>n</italic> = 12)</th>
</tr>
<tr><th align="center">All</th>
<th align="center">Renal (<italic>n</italic> = 7)</th>
<th align="center">Nonrenal (<italic>n</italic> = 13)</th>
</tr></thead>
<tbody>
<tr>
<td colspan="6">Clinical data</td>
</tr>
<tr>
<td> • Age, years</td>
<td>39.5 ± 11</td>
<td>40 ± 12</td>
<td>39 ± 12</td>
<td>ns</td>
<td>58 ± 13</td>
</tr>
<tr>
<td> • Disease duration, years</td>
<td>7.8 ± 7.4</td>
<td>3.2 ± 2.7</td>
<td>10.3 ± 8</td>
<td>0.01</td>
<td>15.9 ± 10</td>
</tr>
<tr>
<td> • Creatinine, mg/dl</td>
<td>1.05 ± 0.9</td>
<td>1.5 ± 1.3</td>
<td>0.8 ± 0.4</td>
<td>0.03</td>
<td>0.67 ± 0.13</td>
</tr>
<tr>
<td> • Blood urea nitrogen, mg/dl</td>
<td>21.1 ± 15.1</td>
<td>29.1 ± 19.2</td>
<td>16.8 ± 11</td>
<td>ns</td>
<td>16.4 ± 5.1</td>
</tr>
<tr>
<td> • 24-hour urine proteins, mg</td>
<td>504 ± 570</td>
<td>1042 ± 689</td>
<td>214 ± 131</td>
<td>0.004</td>
<td>76 ± 26</td>
</tr>
<tr>
<td> • Creatinine clearance, ml/min</td>
<td>84 ± 34.2</td>
<td>60.7 ± 34</td>
<td>96.5 ± 27.9</td>
<td>0.02</td>
<td>90.4 ± 27.1</td>
</tr>
<tr>
<td> • C3 complement, mg/dl</td>
<td>63.7 ± 25</td>
<td>46 ± 22</td>
<td>73 ± 22</td>
<td>0.02</td>
<td>—</td>
</tr>
<tr>
<td> • C4 complement, mg/dl</td>
<td>9.9 ± 5.7</td>
<td>10.7 ± 8.4</td>
<td>9.6 ± 4</td>
<td>ns</td>
<td>—</td>
</tr>
<tr>
<td> • SLEDAI, median (range)</td>
<td>4 (0–12)</td>
<td>8 (4–12)</td>
<td>2 (0–10)</td>
<td>0.007</td>
<td>—</td>
</tr>
<tr>
<td> • SLICC/ACR, median (range)</td>
<td>0.5 (0–7)</td>
<td>1 (0–7)</td>
<td>0 (0–5)</td>
<td>ns</td>
<td>—</td>
</tr>
<tr>
<td colspan="6">Serum markers</td>
</tr>
<tr>
<td> • IL-6, pg/ml</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>ns</td>
<td>4.5 ± 15.5</td>
</tr>
<tr>
<td> • IL-8, pg/ml</td>
<td>5.5 ± 11.4</td>
<td>8.6 ± 14</td>
<td>4.1 ± 10</td>
<td>ns</td>
<td>3 ± 10</td>
</tr>
<tr>
<td> • IL-17, pg/ml</td>
<td>1.1 ± 4.8</td>
<td>3.5 ± 8.5</td>
<td>0</td>
<td>ns</td>
<td>6.4 ± 22.2</td>
</tr>
<tr>
<td> • TNF, pg/ml</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>ns</td>
<td>7.6 ± 26.5</td>
</tr>
<tr>
<td> • sTNFRI, pg/ml</td>
<td>269 ± 99</td>
<td>351 ± 108</td>
<td>231 ± 70</td>
<td>0.01</td>
<td>219.7 ± 110.6</td>
</tr>
<tr>
<td colspan="6">Urinary markers</td>
</tr>
<tr>
<td> • IL-6, pg/ml</td>
<td>41.6 ± 91</td>
<td>50 ± 83</td>
<td>37 ± 98</td>
<td>ns</td>
<td>0</td>
</tr>
<tr>
<td> • IL-8, pg/ml</td>
<td>78 ± 162</td>
<td>211 ± 235</td>
<td>12 ± 34</td>
<td>0.01</td>
<td>6 ± 17</td>
</tr>
<tr>
<td> • IL-17, pg/ml</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>ns</td>
<td>0</td>
</tr>
<tr>
<td> • TNF, pg/ml</td>
<td>3.1 ± 9.1</td>
<td>0</td>
<td>4.6 ± 11</td>
<td>ns</td>
<td>3.5 ± 8.3</td>
</tr>
<tr>
<td> • sTNFRI, pg/ml</td>
<td>259 ± 113</td>
<td>330 ± 108</td>
<td>224 ± 102</td>
<td>0.04</td>
<td>266.3 ± 129.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312474085"><p>SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; SLEDAI: systemic lupus erythematosus disease activity index; SLICC/ACR: Systemic Lupus International Collaborating Clinics/American College of Rheumatology cumulative damage index; IL: interleukin; TNF: tumor necrosis factor; sTNFRI: soluble TNF receptor I. All data are expressed as mean ± standard deviation unless otherwise specified.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The Table shows the main data of participants. In SLE, patients with renal involvement had lower disease duration but higher disease activity, higher serum and urine levels of soluble tumor necrosis factor receptor I (sTNFRI), and higher concentration of interleukin (IL)-8 in urine. Other covariates such as drug use, comorbidities, and antibodies were similar (data not shown).</p>
<p>Vanin-1 expression (<xref ref-type="fig" rid="fig1-0961203312474085">Figure (a)</xref>) was increased in SLE compared to RA (0.17 ± 0.13 versus 0.08 ± 0.04, relative units; <italic>p</italic> = 0.01), and the difference was maintained when SLE patients with renal involvement (0.25 ± 0.15; <italic>p</italic> = 0.01) were compared to RA. In contrast, no differences were found between nonrenal SLE (0.13 ± 0.09; <italic>p</italic> = ns) and RA patients.
<fig id="fig1-0961203312474085" position="float"><label>Figure 1</label><caption><p>Transcript levels of vanin-1 and their correlation (Spearman’s ρ coefficient) with surrogate markers of active renal damage. Vanin-1 mRNA levels in total leukocytes from patients with lupus were higher than in rheumatoid arthritis; highest levels were found in lupus patients with active renal damage. The arithmetic mean of vanin-1/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ratio is illustrated by black squares while error bars denote 1 standard deviation (panel (a)). A moderately strong, positive correlation was found between vanin-1 and the serum levels of blood urea nitrogen (BUN; panel (b)) and creatinine (panel (c)), as well as with the urinary levels of interleukin 8 (IL-8; panel (d)) and 24-hour urine proteins (panel (e)). In contrast, a moderately strong, negative correlation was found with creatinine clearance (panel (f)). Only significant correlations are shown in the graphs.</p></caption><graphic xlink:href="10.1177_0961203312474085-fig1.tif"/>
</fig></p>
<p>In SLE patients, vanin-1 expression notably correlated (<xref ref-type="fig" rid="fig1-0961203312474085">Figure (b–f)</xref>) with blood urea nitrogen, serum creatinine, IL-8 levels in urine, and 24-hour urine proteins, while it was inversely correlated with creatinine clearance. No correlations were significant with overall disease activity (ρ 0.34, –0.17 to 0.71) or cumulative organ damage (ρ 0.09, –0.43 to 0.57). No correlations were found with serum levels of complement C3 (ρ –1.1, –0.6 to 0.3), C4 (ρ –0.23, –0.6 to 0.29), IL-8 (ρ 0.09, –0.4 to 0.5), sTNFRI (ρ 0.38, –0.15 to 0.7), or the urinary concentration of sTNFRI (ρ 0.38, –0.17 to 0.7). In RA patients, vanin-1 expression was not associated with any variables, including those found to be relevant in lupus.</p>
<p>To date, novel molecules such as monocyte chemotactic protein-1 (MCP-1), ceruloplasmin, IL-8, and neutrophil gelatinase-associated lipocalin (NGAL) have been investigated as potential markers of LN. Separately, each has shown moderate ability to reflect LN activity, but combining them with traditional markers significantly increases their diagnostic accuracy.<sup><xref ref-type="bibr" rid="bibr12-0961203312474085">12</xref></sup> Hence, novel markers are necessary to provide noninvasive, highly accurate diagnostic tests to guide diagnosis and therapy of LN.</p>
<p>This short communication is limited by the small number of patients included, lack of follow-up, and absence of healthy controls; however, it supports the hypothesis that vanin-1 mRNA levels in peripheral blood may be a promissory biomarker for LN and gives rationale to measure it in a larger cohort.</p>
</body>
<back>
<sec id="sec1-0961203312474085"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec2-0961203312474085"><title>Conflict of interest</title>
<p>None declared.</p></sec>
<sec id="sec3-0961203312474085"><title>Conflict of Interest Statement</title>
<p>The authors have no conflicts of interest to declare</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312474085"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dall'Era</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>D</given-names></name><name><surname>Levesque</surname><given-names>V</given-names></name><name><surname>Cisternas</surname><given-names>M</given-names></name><name><surname>Wofsy</surname><given-names>D</given-names></name></person-group>. <article-title>Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide</article-title>. <source>Arthritis Care Res (Hoboken)</source> <year>2011</year>; <volume>63</volume>: <fpage>351</fpage>–<lpage>357</lpage>.</citation></ref>
<ref id="bibr2-0961203312474085"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amezcua-Guerra</surname><given-names>LM</given-names></name><name><surname>Springall</surname><given-names>R</given-names></name><name><surname>Arrieta-Alvarado</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus</article-title>. <source>Clin Lab</source> <year>2011</year>; <volume>57</volume>: <fpage>607</fpage>–<lpage>613</lpage>.</citation></ref>
<ref id="bibr3-0961203312474085"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaskow</surname><given-names>BJ</given-names></name><name><surname>Proffit</surname><given-names>JM</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Moses</surname><given-names>EK</given-names></name><name><surname>Abraham</surname><given-names>LJ</given-names></name></person-group>. <article-title>Diverse biological activities of the vascular non-inflammatory molecules – the vanin pantetheinases</article-title>. <source>Biochem Biophys Res Commun</source> <year>2012</year>; <volume>417</volume>: <fpage>653</fpage>–<lpage>658</lpage>.</citation></ref>
<ref id="bibr4-0961203312474085"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>PA</given-names></name><name><surname>Kamsteeg</surname><given-names>M</given-names></name><name><surname>Rodijk-Olthuis</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Expression of the vanin gene family in normal and inflamed human skin: Induction by proinflammatory cytokines</article-title>. <source>J Invest Dermatol</source> <year>2009</year>; <volume>129</volume>: <fpage>2167</fpage>–<lpage>2174</lpage>.</citation></ref>
<ref id="bibr5-0961203312474085"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosohata</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Fujimura</surname><given-names>A</given-names></name></person-group>. <article-title>Vanin-1: A potential biomarker for nephrotoxicant-induced renal injury</article-title>. <source>Toxicology</source> <year>2011</year>; <volume>290</volume>: <fpage>82</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr6-0961203312474085"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosohata</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Fujimura</surname><given-names>A</given-names></name></person-group>. <article-title>Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury</article-title>. <source>J Pharmacol Exp Ther</source> <year>2012</year>; <volume>341</volume>: <fpage>656</fpage>–<lpage>662</lpage>.</citation></ref>
<ref id="bibr7-0961203312474085"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fugmann</surname><given-names>T</given-names></name><name><surname>Borgia</surname><given-names>B</given-names></name><name><surname>Révész</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy</article-title>. <source>Kidney Int</source> <year>2011</year>; <volume>80</volume>: <fpage>272</fpage>–<lpage>281</lpage>.</citation></ref>
<ref id="bibr8-0961203312474085"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr9-0961203312474085"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibañez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Systemic lupus erythematosus disease activity index 2000</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>288</fpage>–<lpage>291</lpage>.</citation></ref>
<ref id="bibr10-0961203312474085"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>809</fpage>–<lpage>813</lpage>.</citation></ref>
<ref id="bibr11-0961203312474085"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <year>1988</year>; <volume>31</volume>: <fpage>315</fpage>–<lpage>324</lpage>.</citation></ref>
<ref id="bibr12-0961203312474085"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Mina</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Association of noninvasive measured renal protein biomarkers with histologic features of lupus nephritis</article-title>. <source>Arthritis Rheum</source> <year>2012</year>; <volume>64</volume>: <fpage>2687</fpage>–<lpage>2697</lpage>.</citation></ref>
</ref-list>
</back>
</article>